Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DEVICE

Argon-Helium Cryoablation

Procedure performed within 7 days before the first dose of PD-1 inhibitor. CT-guided insertion of cryoprobes into the target tumor. Two freeze-thaw cycles: rapid freeze to -135°C to -145°C for 15-20 minutes, followed by thawing.

DRUG

Camrelizumab

200 mg intravenously every 3 weeks for 4 cycles.

DRUG

Platinum-based doublet chemotherapy

"* Non-squamous NSCLC: Pemetrexed (500 mg/m² IV on day 1) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.~* Squamous NSCLC: Gemcitabine (1250 mg/m² IV on days 1 and 8) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.~* Administered for 4 cycles."

Trial Locations (1)

050031

the First Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

The First Hospital of Hebei Medical University

OTHER

NCT07053215 - Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC | Biotech Hunter | Biotech Hunter